Edit
Rodin Therapeutics
https://rodintherapeutics.com/Last activity: 23.04.2024
Probably Closed - Reference to Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the field of neuroscience.
Location: United States, Massachusetts, Cambridge
Total raised: $57.2M
Investors 4
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | Third Poin... | thirdpoint... |
| - | Atlas Vent... | atlasventu... |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.09.2017 | - | $27M | - |
| 06.01.2016 | - | $17.3M | - |
| 29.05.2014 | Series A | $12.9M | - |
Mentions in press and media 13
| Date | Title | Description |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 18.04.2019 | Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta | But last month, Biogen and its partner, Japan’s Eisai, shocked the world by halting the Phase III studies, ENGAGE and EMERGE, after a futility analysis by the program’s independent data monitoring committee showed the trials were likely to ... |
| 16.04.2019 | The trouble with mice as behavioral models for Alzheimer’s and other neurologic diseases | There’s been a lot of talk about overinvestment in interventions aimed at amyloid in the weeks since Biogen discontinued a late-stage study of aducanumab, an experimental therapy for Alzheimer’s disease. Although much of the focus has been ... |
| 20.09.2017 | Term Sheet — Wednesday, September 20 | THE ROBOTS ARE COMING Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop It is so massive—its investors range from a Saudi sovereign wealth fund to Apple—that small stakes are impossible ... |
| 18.09.2017 | Rodin Therapeutics Raises $27M in Financing | Rodin Therapeutics, a Cambridge, MA-based biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, completed a $27m financing round. The round included returning investor Atlas Venture, with further ... |
| 18.09.2017 | Rodin Therapeutics Grabs $27M | CAMBRIDGE, MA, Rodin Therapeutics completes $27 million financing round. >> Click here for more funding data on Rodin >> To export Rodin funding data to PDF and Excel, click here Rodin Therapeutics, a biotechnology compan... |
| 06.01.2016 | Rodin Therapeutics Raises $17.3M in Funding | Rodin Therapeutics, a Cambridge, MA-based biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, raised $17.3m in funding. Backers included Atlas Venture and Biogen. In addition to... |
| 06.10.2015 | Rodin Therapeutics Appoints Adam J. Rosenberg as CEO | The Board of Directors of Rodin Therapeutics, a Cambridge, MA-based biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, has appointed Adam J. Rosenberg as Chief Executive Office... |
| 19.06.2014 | J&J early stage collaborations span 3D printing for orthopedics, brown fat, biosensors | Brown fat as metabolic disorder treatment: Unlike normal fat cells, brown fat cells convert energy from food into heat. Brown fat has been a growing source of interest among scientists as a source of potential therapeutics for obesity and m... |
| 29.05.2014 | Rodin Secures $12.9M Series A Financing | CAMBRIDGE, MA, Biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, has closed a $12.9M Series A financing round. >> Click here for more funding data on Rodin >> To export ... |
Show more